NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SYNCOMF · data 2026-10-30
Syncom Formulation (India) Ltd.
In plain words
Price: 30.0% below its 52-week high of ₹27.49.
Delivery: 30.1% of traded shares were kept for delivery over the last 10 sessions, against 33.3% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹498 cr |
| Net profit (last 12 months) | ₹86 cr |
| Sales growth, 3 years (yearly) | 29.4% |
| Profit growth, 3 years (yearly) | 56.2% |
At a glance
P/E 21.1, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 20.2%, ROCE 16.3%, operating margin 16.3%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 56.2% and sales growth 29.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (20.2%).
- Profit grew 56.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 26.9% over the last 20 sessions vs 21.8% in the 40 before (1.23x); shares delivered per day 0.89x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹1.35 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend
- 30 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹1.35 cr -8.5% next session
- 23 Sept 26Dividend Dividend ₹0.1 (ex-date) -1.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Syncom Formulation (India) Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Syncom Formulation (India) Ltd.'s P/E ratio?
About 21.2, based on the last 12 months' earnings and a price of ₹19.24 (data 2026-10-30).
What is the 52-week high and low of Syncom Formulation (India) Ltd.?
The 52-week high is ₹27.49 and the 52-week low is ₹10.21.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,916 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
Compare SYNCOMF with BETA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SYNCOMF in NSE Scanner →